Retatrutide pen 20mg GLP3 (Triple G)

Retatrutide pen 20 mg - what it is and how it works, scientific information 

Retatrutide pen 20 mg, referred to in the research community as Retatrutide LY3437943, is a novel experimental agonist of three hormone receptors - GLP-1, GIP and glucagon - designed to simultaneously modulate several key metabolic pathways. As a result, retatrutide combines mechanisms responsible for appetite regulation, glucose metabolism and energy expenditure, which may translate into a potent weight-loss effect. Clinical studies have shown that retatrutide can produce promising metabolic and weight-loss effects, well above those achieved by single or dual incretin receptor agonists.

Retatrutide pen 20 mg vs weight loss (research)

Large phase 2 clinical trials found that retatrutide administered once a week for 48 weeks led to significant weight reductions in obese adults, with average decreases of about 22.8-24.2 % of initial weight in the 8 mg and 12 mg dose groups. In more recent phase 3 studies (e.g., TRIUMPH-4), the results were even more spectacular, with average weight decreases reaching as high as 26-28.7 % in groups receiving retatrutide for 68 weeks - more than a quarter of the participants' body weight, while improving functional parameters such as joint pain in people with obesity and knee osteoarthritis. Data from the Phase 2 study also suggest that retatrutide may have a beneficial effect on eating behavior, reducing the frequency of food intake and portion size, and increasing feelings of satiety.

Metabolic effects according to available sources

In addition to weight reduction, studies have shown that retatrutide pen 20 mg, also called retatrutide peptide, also improves metabolic markers including glycemic control and parameters related to lipid metabolism and hepatic steatosis. In specific clinical populations, retatrutide has improved parameters associated with type 2 diabetes and reduced body fat, which is important from the perspective of a comprehensive approach to metabolic disorders.

Retatrutide pen 20 mg safety and side effects observed in the scientific literature

Analyses published in meta-analyses and clinical trials indicate that retatrutide generally has a safety profile similar to other drugs acting on the incretin axis. The most commonly reported side effects are gastrointestinal symptoms such as nausea, diarrhea and vomiting, as well as hypersensitivity or skin reactions. Findings indicate that these symptoms are usually moderate and dose-related, and serious side effects are rare, although full safety profiles will be evaluated in subsequent long-term clinical trials.

Retatrutide pen 20 mg price (research products)

Retatrutide pen 20 mg does not have an official medical price, as it remains an investigational substance, and the available offers are only for products like research use only. High-purity retatrutide in the form of a research powder can be found for sale on the Internet at guide prices of around EUR 80-90 per single vial. The most commonly offered vials containing 5-10 mg of peptide are usually priced in the range of about EUR 100-180, while larger vials, such as 12 mg, reach prices of about EUR 130-200, depending on the manufacturer and claimed purity. More elaborate kits, such as pens containing about 40 mg of peptide, are sometimes significantly more expensive, reaching around €350-380 in some offerings. Larger bulk packs are also available on international research platforms (so-called. bulk), covering tens to hundreds of milligrams, whose prices can range widely - from about €280 to as much as €2,000. Price differences are mainly due to the amount of peptide, the form of the product (powder or pen), the declared purity, the manufacturer, and the terms of sale and shipping. All values quoted are indicative and refer to the research reagent market only.

Retatrutide - clinical perspectives of a triple receptor agonist in the treatment of obesity and metabolic disorders

Retatrutide is among the most intensively studied triple receptor agonists (GLP-1, GIP and glucagon receptor) being evaluated in the context of treating obesity and metabolic disorders. The substance is an investigational medicinal product (IMP), intended for use only in preclinical and clinical studies. Available clinical data indicate that molecules belonging to this class can induce deeper and more sustained weight reduction compared to therapies based on single receptor agonization. The observed effects also include beneficial effects on selected metabolic parameters. Despite the lack of final registration and decisions by regulatory authorities, a steadily growing scientific evidence base positions retatrutide pen 20 mg as an important object for further research into future pharmacological strategies for the treatment of obesity in adults.

See also SLU-PP-332 capsules 500mcg/60caps.

Scientific sources:

1) Triple-Hormone-Receptor Agonist Retatrutide for Obesity (NEJM / PubMed).

https://pubmed.ncbi.nlm.nih.gov/37366315/
It confirms that retatrutide acts on three receptors (GLP-1, GIP, glucagon) and in 48-week studies leads to significant weight reduction in obese subjects.

2) Retatrutide weight loss and other outcomes (phase 2)

https://pubmed.ncbi.nlm.nih.gov/38858523/
It shows the relationship dose-effect - weight reductions of ~22.8 % and 24.2 % at 8 mg and 12 mg after 48 weeks - and liver fat reduction data.

3) TRIUMPH-4 Phase III topline results (news / clinical press)

https://www.pharmexec.com/view/lilly-retatrutide-positive-topline-results-successful-phase-iii-trial
Describes Phase 3 results with weight reduction to ~28.7 % and improved joint function in obese and osteoarthrosis patients.

4) Meta-analysis of once-weekly subcutaneous retatrutide

https://pubmed.ncbi.nlm.nih.gov/39318607/
It confirms significant weight reduction and improvement in metabolic markers, while pointing to more frequent ineffective side effects, such as gastric symptoms.

5) Additional clinical insights & body composition effects

https://pubmed.ncbi.nlm.nih.gov/40609566/
It shows that retatrutide improves fat reduction compared to other drugs and affects body compositions in people with type 2 diabetes. 

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.